Pulmonary hypertension secondary to interstitial lung disease

Expert Review of Respiratory Medicine

Volumn 5, Issue 2, 2011, Pages 179-189

  Shlobin, Oksana A ^a   Nathan, Steven D ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

catheterization; histiocytosis; hypertension; interstitial; Langerhans cell; lung diseases; lymphangioleiomyomatosis; pulmonary; pulmonary fibrosis; research design; sarcoidosis; scleroderma; Swan Ganz; systemic

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ILOPROST; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TEZOSENTAN; UNIPROST; VASCULOTROPIN;

ANTICOAGULATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; HYPOXEMIA; HYPOXIA; INTERSTITIAL LUNG DISEASE; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MORTALITY; OXYGEN CONSUMPTION; OXYGEN THERAPY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SARCOIDOSIS; SMOKING; SPIROMETRY; SURVIVAL RATE; SYNDROME CREST; SYSTEMIC SCLEROSIS;

EID: 79955417680     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.11     Document Type: Review

References (103)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. General principles and recommendations. Am. J. Respir. Crit. Care Med. 165, 277-304 (2002).
2. Thannickal VJ, Toews GB, White ES et al. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 55, 395-417 (2004). (Pubitemid 38316734)
3. Strange C, Highland K. Pulmonary hypertension in ILD. Curr. Opin. Pulm. Med. 11, 452-455 (2005).
4. Simmoneau G, Robins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Card. 54(1), S43-S54 (2009).
5. Shapiro S. Management of pulmonary hypertension resulting from interstital lung disease. Curr. Opin. Pulm. Med. 9, 426-430 (2003). (Pubitemid 36994073)
6. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
7. Chronic cor pulmonale: report of an expert committee. Circulation 27(4), 594-615 (1963).
8. Fartoukh M, Humbert M, Capron F et al. Severe pulmonary hypertension in histiocytosis X. Am. J. Respir. Crit. Care Med. 161, 216-223 (2000). (Pubitemid 30055928)
9. Dauriat G. Lung transplantation for pulmonary Langerhans cell histiocytosis: a multicenter analysis. Transplantation 81(5), 746-750 (2006).
10. Chaowalit N, Pellikka PA, Decker PA et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo. Clin. Proc. 79(10), 1269-1275 (2004). (Pubitemid 39299072)
11. Harari S, Brenot F, Barberis M et al. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest 111(4), 1142-1144 (1997).
12. Nadrous HF, Pellikka PA, Krowka MJ et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128, 2393-2399 (2005). (Pubitemid 41507585)
13. Lettieri C, Nathan SD, Barnett S et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129, 746-752 (2006).
14. Shorr AF, Wainright JL, Cors CS et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur. Respir. J. 30(4), 715-721 (2007). (Pubitemid 351194832)
15. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett S. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131(3), 657-663 (2007). (Pubitemid 46446854)
16. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. 62, 1088-1093 (2003). (Pubitemid 37323574)
17. Chang B, Wigley FM, White B et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J. Rheumatol. 30, 2398-2405 (2003). (Pubitemid 37413900)
18. Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med. 179, 151-157 (2009).
19. Trad S, Amoura Z, Beigelman C et al. PAH is a major mortality factor in diffuse systemic sclerosis, independent of intersitial lung disease. Arthritis Rheum. 54, 184-191 (2006). (Pubitemid 43122201)
20. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 48(2), 516-522 (2003). (Pubitemid 36278021)
21. Handa T, Nagai S, Miki S et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129, 1246-1252 (2006).
22. Shorr AF, Helman DL, Davies DB et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur. Respir. J. 25, 783-788 (2005). (Pubitemid 40667674)
23. Shorr AF, Davies DB, Nathan SD. Predicting mortailty in patients with sarcoidosis awaiting lung transplantation. Chest 124, 922-928 (2003). (Pubitemid 37123310)
24. Sulica R, Teirstein AS, Kakarla S et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128, 1483-1489 (2005). (Pubitemid 41324436)
25. Taveira-DaSilva AM, Hathaway OM, Sachdev V et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 132(5), 1573-1578 (2007). (Pubitemid 350156015)
26. Portier F, Lerebours-Pigeonniere G, Thiberville L et al. Sarcoidosis simulating pulmonary veno-occlusive disease. Rev. Mal. Respir. 8(1), 101-102 (1991).
27. Morgan JM, Griffiths M, du Bois RM et al. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 99, 551-556 (1991).
28. Nunes H, Humbert M, Capron F et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61, 68-74 (2006). (Pubitemid 43106981)
29. Colombat M, Mal H, Groussard O et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum. Path. 38(1), 60-65 (2007). (Pubitemid 44883363)
30. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarc. Vasc. Diff. Lung Dis. 26, 7-19 (2009).
31. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 113, 237-240 (1998). (Pubitemid 28044953)
32. Farber HW, Graven KK, Kokolski G, Korn JH. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J. Rheumatol. 26, 1195-1196 (1999). (Pubitemid 29215090)
33. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog. Cardiovasc. Dis. 45, 225-234 (2002). (Pubitemid 36139818)
34. Mahapatra S, Nishimura RA, Sorajja P et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J. Am. Coll. Cardiol. 47(4), 799-803 (2006). (Pubitemid 43243104)
35. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc. 3, 364-372 (2006). (Pubitemid 43845414)
36. Farkas L, Gauldie J, Voelkel NF et al. Pulmonary hypertension and idiopathic pulmonary fibrosis -a tale of angiogenesis, apoptosis and growth factors. Am. J. Respir. Cell Mol. Biol. DOI:10.1165/rcmb.2010-0365TR (2010) (Epub ahead of print).
37. Yamakami T, Taguchi O, Gabazza EC et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease: relation with pulmonary HTN during exercise. Eur. Respir. J. 10, 2055-2060 (1997). (Pubitemid 27406441)
38. MacLean MR. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J. Lab. Clin. Med. 134, 105-114 (1999).
39. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 175, 875-880 (2007).
40. Nathan SD, Shlobin OA, Ahmad S et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131, 657-663 (2007). (Pubitemid 46446854)
41. Galie N, Manes A, Farahani KV et al. PAH associated with CTDs. Lupus 14, 713-717 (2005).
42. Fahy GJ, Marwick T, McCreery CJ et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 109, 62-66 (1996). (Pubitemid 26017594)
43. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in ling fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 170(4), 360-365 (2004). (Pubitemid 39214607)
44. Magro CM, Allen J, Pope-Harman A et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol. 119, 556-567 (2003). (Pubitemid 37046407)
45. Panos R. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med. 88(4), 396-404 (1990). (Pubitemid 20147276)
46. Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest 123, 1758-1763 (2003). (Pubitemid 36549800)
47. Mejía M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136(1), 10-15 (2009).
48. Perez-Padilla R, West P, Lertzman M et al. Breathing during sleep in patients with interstitial lung disease. Am. Rev. Respir. Dis. 132, 224-229 (1985). (Pubitemid 15229371)
49. Minai OA, Santucruz JF, Thuita L et al. Severe pulmonary hypertension in IPF: characteristics and implications. Presented at: ISHLT 29th Annual Meeting and Scientific Sessions. Paris, France, 22-25 April 2009.
50. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension. Chest 138, 1078-1085 (2010).
51. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Resp. Med. 103, 180-186 (2009).
52. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann. Rheum. Dis. 62, 97-99 (2003). (Pubitemid 36135382)
53. Zisman DA, Karlamangla AS, Ross DJ et al. High resolution CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 132, 773-779 (2007).
54. Yock P. Noninvasive estimation of the right ventriculat systolic pressure by doppler ultrasound in patients with tricuspid regurgitation. Circulation 70(4), 657-662 (1984). (Pubitemid 14020664)
55. Fisher MR, Forfia PR, Chamera E et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 179(7), 615-621 (2009).
56. Arcasoy S, Chrstie J, Ferrari V et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 167, 735-740 (2003). (Pubitemid 36801751)
57. Corte TJ, Wort SJ, Gatzoulis MA et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 64(10), 883-888 (2009).
58. Devaraj A, Wells AU, Meister MG et al. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology 254(2), 609-616 (2010).
59. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 40S-47S (2004). (Pubitemid 38759716)
60. Badesch DB, Abman SH, Simonneau G et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131, 1917-1928 (2007). (Pubitemid 46981654)
61. Hamada K, Nagai S, Tanaka S et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131, 650-656 (2007). (Pubitemid 46446853)
62. Bye PT, Issa F, Berthon-Jones M et al. Studies of oxygenation during sleep in patients with interstitial lung disease. Am. Rev. Respir. Dis. 129, 27-32 (1984). (Pubitemid 14176497)
63. Papadopoulis CE, Pitsiou G, Karamitsos TD et al. Left ventricular diastolic dysfunction in IPF: a tissue doppler ECG study. Eur. Respir. J. 31, 701-706 (2008).
64. Corte TJ, Talbot S, Wort SJ et al. Nocturnal desaturation is associated with pulmonary hypertension in patients with mild to moderate interstitial lung disease. Am. J. Respir. Crit. Care Med. 179, A4057 (2009).
65. Shitrit D, Rusanov V, Peled N et al. The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis. J. Heart Lung Transplant. 28, 328-333 (2009).
66. Kliment CR, Oury TD. Oxidative stress, extracellualr matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 49(5), 707-717 (2010).
67. Benyuones B, Crestani B, Couvelard A, et al. Steroid-responsive pulmonary hypertension in a patient with Langerhans cell granulomatosis (histiocytosis X). Chest 110, 284-286 (1996).
68. Pulmonary hypertension and limited scleroderma. J. Rheumatol. 26, 1195-1196 (1999).
69. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog. Cardiovasc. Dis. 45, 225-234 (2002). (Pubitemid 36139818)
70. Mahapatra S, Nishimura RA, Sorajja P et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J. Am. Coll. Cardiol. 47(4), 799-803 (2006). (Pubitemid 43243104)
71. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc. 3, 364-372 (2006). (Pubitemid 43845414)
72. Farkas L, Gauldie J, Voelkel NF et al. Pulmonary hypertension and idiopathic pulmonary fibrosis -a tale of angiogenesis, apoptosis and growth factors. Am. J. Respir. Cell Mol. Biol. DOI:10.1165/rcmb.2010-0365TR (2010) (Epub ahead of print).
73. Yamakami T, Taguchi O, Gabazza EC et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease: relation with pulmonary HTN during exercise. Eur. Respir. J. 10, 2055-2060 (1997). (Pubitemid 27406441)
74. MacLean MR. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J. Lab. Clin. Med. 134, 105-114 (1999).
75. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 175, 875-880 (2007).
76. Nathan SD, Shlobin OA, Ahmad S et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131, 657-663 (2007). (Pubitemid 46446854)
77. Galie N, Manes A, Farahani KV et al. PAH associated with CTDs. Lupus 14, 713-717 (2005).
78. Fahy GJ, Marwick T, McCreery CJ et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 109, 62-66 (1996). (Pubitemid 26017594)
79. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in ling fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 170(4), 360-365 (2004). (Pubitemid 39214607)
80. Magro CM, Allen J, Pope-Harman A et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol. 119, 556-567 (2003). (Pubitemid 37046407)
81. Panos R. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med. 88(4), 396-404 (1990). (Pubitemid 20147276)
82. Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest 123, 1758-1763 (2003). (Pubitemid 36549800)
83. Mejía M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136(1), 10-15 (2009).
84. Perez-Padilla R, West P, Lertzman M et al. Breathing during sleep in patients with interstitial lung disease. Am. Rev. Respir. Dis. 132, 224-229 (1985). (Pubitemid 15229371)
85. Minai OA, Santucruz JF, Thuita L et al. Severe pulmonary hypertension in IPF: characteristics and implications. Presented at: ISHLT 29th Annual Meeting and Scientific Sessions. Paris, France, 22-25 April 2009.
86. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension. Chest 138, 1078-1085 (2010).
87. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Resp. Med. 103, 180-186 (2009).
88. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann. Rheum. Dis. 62, 97-99 (2003). (Pubitemid 36135382)
89. Zisman DA, Karlamangla AS, Ross DJ et al. High resolution CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 132, 773-779 (2007).
90. Yock P. Noninvasive estimation of the right ventriculat systolic pressure by doppler ultrasound in patients with tricuspid regurgitation. Circulation 70(4), 657-662 (1984). (Pubitemid 14020664)
91. Fisher MR, Forfia PR, Chamera E et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 179(7), 615-621 (2009).
92. Arcasoy S, Chrstie J, Ferrari V et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 167, 735-740 (2003). (Pubitemid 36801751)
93. Corte TJ, Wort SJ, Gatzoulis MA et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 64(10), 883-888 (2009).
94. Devaraj A, Wells AU, Meister MG et al. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology 254(2), 609-616 (2010).
95. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 40S-47S (2004). (Pubitemid 38759716)
96. Badesch DB, Abman SH, Simonneau G et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131, 1917-1928 (2007). (Pubitemid 46981654)
97. Hamada K, Nagai S, Tanaka S et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131, 650-656 (2007). (Pubitemid 46446853)
98. Bye PT, Issa F, Berthon-Jones M et al. Studies of oxygenation during sleep in patients with interstitial lung disease. Am. Rev. Respir. Dis. 129, 27-32 (1984). (Pubitemid 14176497)
99. Papadopoulis CE, Pitsiou G, Karamitsos TD et al. Left ventricular diastolic dysfunction in IPF: a tissue doppler ECG study. Eur. Respir. J. 31, 701-706 (2008).
100. Corte TJ, Talbot S, Wort SJ et al. Nocturnal desaturation is associated with pulmonary hypertension in patients with mild to moderate interstitial lung disease. Am. J. Respir. Crit. Care Med. 179, A4057 (2009).
101. Shitrit D, Rusanov V, Peled N et al. The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis. J. Heart Lung Transplant. 28, 328-333 (2009).
102. Kliment CR, Oury TD. Oxidative stress, extracellualr matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 49(5), 707-717 (2010).
103. Benyuones B, Crestani B, Couvelard A, et al. Steroid-responsive pulmonary hypertension in a patient with Langerhans cell granulomatosis (histiocytosis X). Chest 110, 284-286 (1996). (Pubitemid 26249339)